SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending amid widespread discussion and conflicting reports regarding a major deal with AI chip startup Groq, debated as either a $20 billion acquisition or a strategic licensing agreement. The community is sharply divided, with bulls touting it as a genius move to solidify NVIDIA's dominance in AI inference and talent acquisition, while bears decry it as a desperate, overpriced gambit. This strategic play aims to further cement NVIDIA's leadership across the entire AI hardware lifecycle, from training to the increasingly crucial inference market.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is actively trending as community sentiment is fueled by technical indicators like anticipated "golden crosses" and calls for a significant breakout. Recent reports of users moving their coins to self-custody wallets due to security concerns and exchange transfer issues are also driving conversation. While many expect a rally for the "digital silver," others remain skeptical of its current performance.

Ethereum Classic

Ethereum Classic ($ETC) is trending amidst intense community debate, fueled by recent price volatility and its surprising appearance as a top trending asset. Many long-term holders express deep frustration over its sustained underperformance compared to other major cryptocurrencies, while a segment of the community remains strongly bullish, viewing current price levels as a significant discount and a "loading zone" before an anticipated breakout.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust (SLV) is experiencing intense bullish momentum, driven by spot silver prices reaching new all-time highs and upcoming Chinese export restrictions. This rally is further fueled by booming industrial demand from EV batteries, solar, and AI data centers, sparking community debate over a potential 'silver squeeze' versus an impending sharp pullback.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending following the significant FDA approval of YARTEMLEA, making it the first and only approved treatment for a life-threatening post-transplant complication in both adults and children. The community is actively discussing the drug's blockbuster potential due to its lack of competition and the company's validated pipeline, alongside hopes for a short squeeze and potential buyout speculation, particularly from existing partner Novo Nordisk. Excitement is building ahead of the upcoming conference call where further details, including pricing, are anticipated.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending following recent analyst upgrades and price target increases, with its CEO's media appearances highlighting key partnerships like OpenTable and potential future announcements at CES 2026. The community is engaged in a polarized discussion, weighing the company's "Agentic AI" technology, robust revenue growth, and zero-debt status against persistent short interest and recent price underperformance. Despite the division, many foresee significant long-term growth as the company expands its voice AI solutions across various sectors.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is a major trending topic as significant options expirations are driving notable short-term volatility and ongoing price debate. The community remains divided, with many bulls anticipating a strong breakout and long-term institutional accumulation once expiration pressure subsides, while bears highlight persistent selling pressure and perceived market manipulation.

ProShares Trust - ProShares Bitcoin ETF

ProShares Bitcoin Strategy ETF

BITO is a focal point of conversation as investors anticipate its substantial monthly dividend, with many actively buying on recent dips and viewing current volatility as an accumulation opportunity. The community widely discusses the ETF's dividend payout in relation to its price movements around the ex-dividend date, while maintaining a long-term bullish outlook on Bitcoin's potential for future highs amid ongoing institutional adoption.

Boundless is a universal protocol that brings ZK to every chain. Using Boundless, developers can create expressive, high-throughput applications that bypass traditional block size/gas limits.  Developers submit proof requests and provers compete to fulfill them, earning direct rewards and protocol-level incentives through proof of verifiable work.  By abstracting away the complexity of proof generation, aggregation, and onchain settlement, Boundless allows developers to build without worrying about underlying infrastructure, while provers provide strong liveness guarantees, censorship-resistance, and continuously improve the cost curve driven by open market dynamics.  This architecture decouples execution from consensus and introduces a new paradigm for verifiable computing. As the number of Boundless prover nodes grows, the total capacity of the protocol increases, scaling compute across every chain.

Boundless

ZKC is trending due to its recently launched mainnet, positioning it as a key Ethereum scaling solution aiming to capture market share from competitors. The community is actively discussing its potential for a major reversal and breakout, while simultaneously debating concerns over recent price action and perceived lack of sustained volume.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

The Defiance Daily Target 2X Long SMCI ETF ($SMCX) is trending amid strong bullish sentiment for its underlying asset, Super Micro Computer ($SMCI), driven by positive news like Nvidia's China chip shipments and significant AI infrastructure investments. Traders are actively debating its extreme volatility and decay concerns, with many viewing current price levels as a "buy the dip" opportunity for substantial gains as they anticipate an AI sector rally.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Harbor Capital Advisors Inc. Has $3.76 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM

Harbor Capital Advisors Inc. trimmed its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 57.0% in the third quarter, according to the company in its most recent filing...

Equities Analysts Offer Predictions for RYTM FY2025 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Analysts at HC Wainwright decreased their FY2025 earnings per share estimates for Rhythm Pharmaceuticals in a report issued on Monday...

Voya Investment Management LLC Has $22.38 Million Stake in Rhythm Pharmaceuticals, Inc. $RYTM

Voya Investment Management LLC lessened its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 9.2% during the third quarter, according to its most recent filing with the...

Assenagon Asset Management S.A. Sells 13,870 Shares of Rhythm Pharmaceuticals, Inc. $RYTM

Assenagon Asset Management S.A. cut its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 5.8% during the 3rd quarter, according to its most recent Form 13F filing...

Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $167.00 at Citizens Jmp

Citizens Jmp lifted their target price on Rhythm Pharmaceuticals from $141.00 to $167.00 and gave the company a "market outperform" rating in a research report on Friday...

Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Needham & Company LLC upped their price target on Rhythm Pharmaceuticals from $120.00 to $145.00 and gave the stock a "buy" rating in a report on Thursday...

<ul class="summary-bullets"><li>The company said that reduction in body mass index as well as hyperphagia or extreme, insatiable, or excessive hunger that does not go away after eating was observed at month 3 and month 6 in the trial.</li><li>The company said that the results are supportive of a late-stage registrational trial.&nbsp;</li><li>Bank of America subsequently raised its price target on Rhythm to $140 from $127 while keeping a ‘Buy’ rating on the shares.</li></ul><p>Shares of Rhythm Pharmaceuticals, Inc. (RYTM) jumped 14% on Thursday after the company announced that its mid-stage study evaluating Setmelanotide in Prader-Willi Syndrome patients showed reduction in weight and hyperphagia.</p><p>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-preliminary-data-exploratory">said</a> that the reduction in body mass index as well as hyperphagia or extreme, insatiable, or excessive hunger that does not go away after eating was observed at the third and sixth-month mark in the trial. The company said that the results are supportive of a late-stage registrational trial.</p><h2 class="st-heading-2">Trial Design</h2><p>The company enrolled 18 patients with Prader-Willi Syndrome (PWS) in the ongoing 52 week trial. Of this, 17 patients remain enrolled on active Setmelanotide therapy and the company will share additional data in the first half of 2026, it added.</p><p>PWS is a rare genetic disorder requiring lifelong management and causing poor muscle tone and feeding issues in infancy, followed by relentless hunger (hyperphagia) and severe obesity in childhood, alongside developmental delays, learning disabilities, and distinctive behavioral problems. PWS is estimated to affect approximately 400,000 people worldwide and approximately 20,000 people in the United States, as per Rhythm.</p><p>The company said that safety and tolerability profile of Setmelanotide therapy in the trial was consistent with the drug’s established clinical profile. In the United States, Setmelanotide is already indicated to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to certain conditions including Bardet-Biedl syndrome.</p><p>Rhythm is also looking to evaluate its experimental therapy RM-718 in PWS and expects the first patient with PWS to enter screening for this study in December.</p><h2 class="st-heading-2">Expert Take</h2><p>Bank of America subsequently raised its price target on Rhythm to $140 from $127 while keeping a ‘Buy’ rating on the shares. The firm, which is "encouraged" by the preliminary update, argues that a successful late-stage study in PWS would "offer an attractive commercial opportunity."</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around RYTM jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.</p><figure class="image"><img style="aspect-ratio:586/59;" src="data:image/png;base64,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" width="586" height="59" alt="RYTM’s Sentiment Meter and Message Volume as of 12:46 p.m. ET on Dec. 11, 2025 | Source: Stocktwits"><figcaption>RYTM’s Sentiment Meter and Message Volume as of 12:46 p.m. ET on Dec. 11, 2025 | Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/RYTM">RYTM stock</a> has more than doubled this year.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/apollo-global-management-weighs-ipo-or-sale-of-invited-in-potential-deal-that-could-top-3-billion/cLIxS8NREnC">Apollo Global Management Weighs IPO Or Sale Of Invited In Potential Deal That Could Top $3B: Report</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration, the Rhythm Pharmaceuticals company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder 

 The company was studying the therapy in Prader-Willi Syndrome, a rare genetic disorder requiring lifelong management.

Equity

 The company was studying the therapy in Prader-Willi Syndrome, a rare genetic disorder requiring lifelong management.


Rhythm Pharmaceuticals (NASDAQ:RYTM) Hits New 12-Month High - Here's Why

Rhythm Pharmaceuticals (NASDAQ:RYTM) Hits New 12-Month High - Should You Buy...

Rhythm Pharmaceuticals (NASDAQ:RYTM) Hits New 1-Year High - What's Next?

Rhythm Pharmaceuticals (NASDAQ:RYTM) Hits New 52-Week High - Here's Why...

Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On Thursday

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

RYTM
Rhythm Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RYTM News

RYTMRhythm Pharmaceuticals Inc.